Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Lymphoma 2Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms 2Sarcoma, Alveolar Soft Part 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 19pembrolizumab 16Carboplatin 12Bevacizumab 8lenvatinib 6rucaparib 5Nivolumab 5Megestrol Acetate 5Radiation 4Indocyanine Green 4Gemcitabine 4Cisplatin 4tisotumab vedotin 3temsirolimus 3Sirolimus 3Sentinel Lymph Node Biopsy 3Magnetic Resonance Spectroscopy 3Doxorubicin 3olaparib 2niraparib 2ixabepilone 2iso-sulfan blue 2irosustat 2epacadostat 2durvalumab 2copanlisib 2Trastuzumab 2Taxes 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Endometrial Neoplasms × Pyridoxine × Clear all
NCT00245050 2011-12-30

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Case Comprehensive Cancer Center

Phase 3 Completed
34 enrolled 9 charts
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡